Sugi Predict

Sugi Predict / Compounds / SCHEMBL2737366

SCHEMBL2737366

SCHEMBL2737366

CC(=O)c1cccc(C(C)C)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 1/20 0.51
▸ RXRB P28702 1/20 0.51
▸ RXRG P48443 1/20 0.51
▸ ALDH1A1 P00352 6/20 0.50
▸ SMN1; SMN2 Q16637 5/20 0.50
▸ MAPT P10636 3/20 0.50
▸ KDM4E B2RXH2 2/20 0.50
▸ CYP3A4 P08684 2/20 0.50
▸ HPGD P15428 2/20 0.50
▸ TP53 P04637 2/20 0.50
▸ TDP1 Q9NUW8 2/20 0.50
▸ MDM4 O15151 1/20 0.50
▸ CA1 P00915 1/20 0.50
▸ CA2 P00918 1/20 0.50
▸ TYR P14679 1/20 0.50
▸ ALOX15 P16050 1/20 0.50
▸ ALOX12 P18054 1/20 0.50
▸ CA5A P35218 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ HDAC4 P56524 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrogen Peroxide SCHEMBL9061056 0.98 RXRA (0.54) RXRARXRBRXRGALDH1A1SMN1; SMN2
Ethane SCHEMBL5407515 0.98 RXRA (0.50) RXRARXRBRXRGALDH1A1SMN1; SMN2
SCHEMBL11816271 0.86 MEN1 (0.56) ALDH1A1SMN1; SMN2MAPTKDM4ECYP3A4
SCHEMBL2716146 0.86 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2MAPTKDM4ECYP3A4
SCHEMBL11756980 0.85 MAPT (0.65) RXRARXRBRXRGALDH1A1SMN1; SMN2
SCHEMBL21374188 0.84 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2MAPTKDM4ECYP3A4
SCHEMBL28999793 0.84 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2MAPTKDM4ECYP3A4
SCHEMBL597590 0.84 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2MAPTKDM4ECYP3A4
SCHEMBL27845336 0.84 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2MAPTKDM4ECYP3A4
SCHEMBL3887369 0.83 RXRA (0.51) RXRARXRBRXRGALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110724154-A Polysubstituted pyrrolo [3,4-d ] isoxazole derivative and synthetic method thereof 湖北科技学院 2020-01-24 — — CN claimed
JP-58126830-A — — None — — JP disclosed
EP-4648762-A2 PPARG MODULATORS University of Florida Research Foundation, Incorporated (US) 2025-11-19 — — EP disclosed
US-20250257039-A1 MCT4 INHIBITORS FOR TREATING DISEASE Vettore, LLC 2025-08-14 — — US disclosed
CN-223170900-U 1- (3-Isopropylphenyl) ethanone reation kettle convenient to clean 昆山亚香香料股份有限公司 2025-08-01 — — CN disclosed
US-12187682-B2 MCT4 inhibitors for treating disease Vettore, LLC (US) 2025-01-07 — — US disclosed
EP-4442318-A2 HETEROCYCLIC INHIBITORS OF MCT4 Vettore, LLC (US) 2024-10-09 — — EP disclosed
WO-2024151519-A2 PPARG MODULATORS UNIVERSITY OF FLORIDA RESEARCH FOUNDATIN, INCORPORATED (US) 2024-07-18 — — WO disclosed
WO-2024151519-A2 PPARG MODULATORS UNIVERSITY OF FLORIDA RESEARCH FOUNDATIN, INCORPORATED (US) 2024-07-18 — — WO disclosed
US-12037323-B2 Uracil derivatives as Mer-AXL inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2024-07-16 — — US disclosed
US-20070135631-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-14 — — US disclosed
CN-1942825-A Resist composition MITSUBISHI GAS CHEMICAL CO (JP) 2007-04-04 — — CN disclosed
EP-1764366-A2 Thrombin receptor antagonists SCHERING CORPORATION (US) 2007-03-21 — — EP disclosed
US-7173031-B2 Pyrrolotriazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-06 — — US disclosed
US-20070015797-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method CHENG PETER T 2007-01-18 — — US disclosed
EP-1233014-A1 ASYMMETRIC ORGANIC PEROXIDE, CROSSLINKING AGENT COMPRISING THE SAME, AND METHOD OF CROSSLINKING WITH THE SAME NOF CORPORATION (JP) 2002-08-21 — — EP disclosed
EP-0036312-B1 PROCESS FOR PRODUCING P-NITROANILINE MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1983-09-28 — — EP disclosed
JP-S58126830-A PREPARATION OF 3-HYDROXYACETOPHENONE ASAHI CHEM IND CO LTD 1983-07-28 — — JP disclosed
US-4370502-A NITRATION OF AN ALPHA-METHYLBENZALANILINE USING NITRIC ACID, ANALIPHATIC HALOGEN SOLVENT AND SULFURIC ACID; HYDROLYSIS MITSUI PETROCHEMICAL INDUSTRIES LTD. (JP) 1983-01-25 — — US disclosed
EP-0036312-A2 Process for producing p-nitroaniline MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1981-09-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187682-B2 MCT4 inhibitors for treating disease SLC16A1, SLC16A3, SLC16A7 RXRA 4536/4885RXRB 4336/4885RXRG 4374/4885
US-20250257039-A1 MCT4 INHIBITORS FOR TREATING DISEASE SLC16A1, SLC16A3, SLC16A7 RXRA 4536/4885RXRB 4336/4885RXRG 4374/4885
US-20070135631-A1 HETEROCYCLIC CETP INHIBITORS CETP, CES1, NPC1 RXRA 2389/4885RXRB 1764/4885RXRG 2156/4885
US-12037323-B2 Uracil derivatives as Mer-AXL inhibitors MERTK, DAPK1, AXL RXRA 2655/4885RXRB 2234/4885RXRG 2661/4885
US-20070015797-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method GPR119, LIPC, ACACA RXRA 91/4885RXRB 127/4885RXRG 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.